Medifast Inc. (MED) is a leading American nutrition and weight loss management company that offers meal plans and products aimed at promoting healthier living. Publicly traded on the New York Stock Exchange under the symbol MED, the company has carved out a niche for itself in the health and wellness sector with its evidence-based interventions for weight management.
Founded in 1980, Medifast Inc. started its journey in Owings Mills, Maryland, under the insightful leadership of Dr. William Vitale. Initially, the company operated by selling its products directly to doctors, who would then advocate them to patients aiming to manage their weight. However, over time, the company expanded its business model to direct sales to customers via the internet and through call centers.
One of the standout services offered by Medifast Inc. is its well-known 'OPTAVIA' system, which houses a community of like-minded, health-oriented individuals aiming for sustainable weight loss and wellness. The diet plans offered under this program are scientifically designed to provide the necessary nutrients while promoting weight loss through meal replacements.
The extraordinary success of 'OPTAVIA' can be attributed to the fact that clients receive the support of a dedicated coach who guides them through their weight loss journey and helps them make important lifestyle changes. Moreover, the community aspect of the program provides additional motivation and fosters a sense of belonging among its members.
Medifast Inc. has demonstrated consistent growth and success, showcasing its ability to recognize and adapt to market trends in the wellness industry. The company has also shown a strong commitment to quality and safety by investing in scientific research and only sourcing the best ingredients for its products. As a testament to its dedication to promoting good health, the company received BD's Supplier of the Year award in 2020.
Despite the challenging economy and dynamic business environment, Medifast Inc. has remained resilient and robust, demonstrating a strong financial performance with steady revenue growth. Its proven effective approach to weight loss and wellness combined with the strength of its business model have positioned Medifast Inc. as a leader in its industry – a role that it continues to fulfill with great success.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Medifast (NYSE:MED) shares recently climbed above their 200-day moving average, reaching $12.48 before closing at $12.15, compared to an average of $11.28. Despite this technical performance, analyst sentiment remains cautious with a "Reduce" consensus rating and a $12.00 price target. The company recently exceeded quarterly earnings expectations, reporting a loss of $0.28 per share against an anticipated $0.65 loss, and revenue of $76.38 million.
Medifast (NYSE:MED) stock recently crossed above its 200-day moving average, reaching $12.20, although analysts maintain a "Reduce" consensus rating with a $12.00 target price. The company reported better-than-expected quarterly earnings but continues to face negative margins and has issued negative EPS guidance. Despite this, insider buying has increased, with substantial purchases by a director and other insiders in the past three months.
Medifast (NYSE:MED) stock recently crossed above its 200-day moving average, trading at $12.6250 with a 200-day average of $11.15. Despite this technical indicator, analysts maintain a "Reduce" consensus rating with an average price target of $12.00, due to the company's unprofitability and negative earnings expectations for fiscal 2026. However, recent quarterly results exceeded revenue and EPS estimates, and insiders have purchased a significant number of shares.
Medifast (MED) shares have dropped 5.1% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss but a significant year-over-year revenue decline due to fewer active OPTAVIA coaches, although coach productivity improved. Medifast faces continued challenges from GLP-1 weight-loss medications and projects continued losses for 2026, with anticipated profitability improvements starting in Q4 2026.
Medifast (MED) shares have dropped 7.6% since its last earnings report, underperforming the S&P 500 despite narrower-than-expected Q2 2026 losses and improved coach productivity. The company's revenue declined due to a smaller coach network and broader industry pressures like GLP-1 weight-loss medications, but management expects a return to profitability in Q4 2026 and beyond. Medifast has a Zacks Rank #2 (Buy), with estimates trending upward.
Medifast Director Parsa Kiai recently purchased 43,150 shares of Medifast stock for $529,019, increasing his direct ownership by 6.5%. This transaction follows three other purchases made in August, bringing his total recent buying activity to over 120,000 shares. Despite the insider buying and better-than-expected quarterly revenue, analysts maintain a "Reduce" rating for Medifast with a target price of $12.00.
Medifast Director Parsa Kiai recently purchased 4,329 shares of the company's stock for $12.00 per share, totaling $51,948. This transaction increased his holdings to 665,517 shares. Despite exceeding analysts' quarterly revenue and EPS estimates, Medifast continues to face a "Reduce" consensus rating from analysts, with expected losses through fiscal 2028, though earnings forecasts have shown improvement.
Medifast (MED) is transitioning strategically towards metabolic health with its new 3.0 strategy, including the launch of the consumer brand Trilivy and the Medifast Metabolic Health Institute. The company aims to broaden its offerings for coaches and clients, addressing the needs of those on GLP-1 medications, transitioning off them, or seeking non-drug pathways, particularly focusing on targeted fat loss and lean mass preservation. This shift is expected to open new growth avenues, supported by positive trends and a strong Zacks Rank #2 (Buy) recommendation despite a projected decline in current fiscal year earnings.